Gamma frequency sits at the center of this dementia and brain health question.

Gamma frequency stimulation—specifically 40 Hz audiovisual stimulation—is emerging as a promising intervention for Alzheimer’s disease based on recent clinical evidence. A two-year study of five mild Alzheimer’s patients receiving one hour of daily 40 Hz stimulation showed cognitive preservation in three patients compared to comparable patients in national databases, with significant reductions in tau protein levels in two patients who provided plasma samples. While these results are preliminary, they represent meaningful progress in a field where treatment options remain limited.

The approach works through a method called GENUS (sensory gamma stimulation), which combines light and sound at specific frequencies to stimulate the brain’s neural networks. The theoretical basis is solid: preclinical research shows that 40 Hz stimulation can reduce amyloid-beta burden by 37–53 percent, enhance neuronal synchrony, and improve synaptic plasticity. This article explores what we know about gamma frequency stimulation, the clinical evidence supporting it, and what the ongoing Phase III trials mean for patients and caregivers managing Alzheimer’s disease.

How Does 40 Hz Stimulation Target Alzheimer’s Pathology?
What Clinical Evidence Exists So Far?
What Does the Preclinical Research Tell Us About Mechanism?
How Does Gamma Stimulation Compare to Current Alzheimer’s Treatments?
What Are the Important Limitations and Unknowns?
What Is the Role of Patient Selection and Disease Stage?
What Do Ongoing Trials Mean for the Field?
Conclusion

How Does 40 Hz Stimulation Target Alzheimer’s Pathology?

At the molecular level, gamma frequency stimulation addresses two of Alzheimer’s disease’s primary destructive processes: amyloid-beta accumulation and tau protein tangles. When the brain is stimulated at 40 Hz—a frequency within the gamma band of brain wave activity—research shows that it can inhibit tau protein phosphorylation, the process that causes tau to misfold and form the characteristic tangles that damage neurons. Additionally, the stimulation enhances the glymphatic system, the brain’s waste-clearing mechanism, which helps remove accumulated amyloid-beta plaques.

The mechanism appears to work through synchronizing neural networks. When neurons fire together at 40 Hz, they strengthen their connections (synaptic plasticity) and improve coordinated activity across brain regions important for memory and cognition. This is why the stimulation is delivered as audiovisual input—the combination of light and sound is more effective at driving synchronized 40 Hz activity than either stimulus alone. The lack of adverse events reported in current studies suggests this approach is mechanistically sound and safe, at least for the duration tested.

How Does 40 Hz Stimulation Target Alzheimer's Pathology?

What Clinical Evidence Exists So Far?

The most recent clinical data comes from a phase II trial where patients with Alzheimer’s disease exposed to 40 Hz light and sound experienced significant slowing of brain atrophy compared to untreated controls, along with improvements on some cognitive measures. The two-year open-label extension study of five mild Alzheimer’s patients provides more detailed outcome data: three patients showed cognitive measures that remained significantly higher than comparable patients in a national database, suggesting the stimulation may help preserve cognitive function over time. However, these results come with important caveats.

The studies involve small sample sizes, lack placebo controls (the most recent data is from an open-label extension), and have not yet demonstrated cognitive reversal—only preservation or slowing of decline. The two patients who showed significant tau reduction had provided plasma samples, meaning tau improvements were documented biochemically rather than through cognitive testing alone. Cognito Therapeutics is currently conducting a pivotal Phase III trial nationwide, measuring white matter preservation, which will provide more robust evidence of efficacy. Until those results are published, gamma stimulation remains an experimental intervention rather than an approved treatment.

What Does the Preclinical Research Tell Us About Mechanism?

Laboratory and animal model studies provide the theoretical foundation supporting why gamma stimulation might work. research published in Nature and other peer-reviewed journals demonstrates that multisensory gamma stimulation promotes glymphatic clearance—the brain’s natural cleaning process—which removes amyloid and other toxic protein accumulations. The same studies show that 40 Hz stimulation enhances neuronal network synchrony and synaptic plasticity, improving learning and memory performance in preclinical models.

One key finding is the specificity of the frequency. While studies have tested other stimulation frequencies, the 40 Hz frequency appears particularly effective at triggering the neural and glymphatic responses associated with improved brain health. This isn’t arbitrary; 40 Hz corresponds to a natural brain rhythm associated with attention and perception, so it may enhance the brain’s intrinsic plasticity mechanisms. The consistency of results across multiple independent research groups worldwide strengthens confidence in the mechanism, even though human clinical translation is still early.

What Does the Preclinical Research Tell Us About Mechanism?

How Does Gamma Stimulation Compare to Current Alzheimer’s Treatments?

The existing pharmacological treatments for Alzheimer’s—including lecanemab and other monoclonal antibodies—target amyloid-beta directly but require intravenous infusion, carry risks of amyloid-related imaging abnormalities (ARIA), and show modest cognitive slowing in clinical trials. Gamma stimulation, by contrast, is non-invasive, requires no needles or infusions, and has shown no adverse events in the studies published to date. The trade-off is that gamma stimulation’s efficacy data is less robust; it involves smaller patient numbers and less rigorous trial designs than the Phase III trials supporting current medications.

Another comparison point is cost and accessibility. Intravenous monoclonal antibody treatments are expensive and require regular clinic visits for infusion and brain imaging surveillance. If gamma stimulation proves effective in Phase III trials, it could potentially be delivered at home via a wearable or bedside device—something that would dramatically improve accessibility for patients in rural areas or those with mobility limitations. However, the psychological burden of daily one-hour treatment sessions should not be minimized; patient adherence could be challenging for some.

What Are the Important Limitations and Unknowns?

The current evidence is limited by small sample sizes and short follow-up periods. The two-year study involved only five patients, and while the results are encouraging, five patients cannot establish statistical significance or rule out chance findings. Additionally, nearly all current data involves mild cognitive impairment or mild dementia; it remains unknown whether gamma stimulation would be effective in moderate or severe Alzheimer’s disease. The brain atrophy may be less amenable to reversal at advanced stages, even if stimulation could slow progression in earlier disease.

Long-term safety data are also incomplete. While no adverse events occurred during the study periods reported, longer follow-up is needed to identify any delayed or subtle neurological effects from repeated 40 Hz stimulation. Additionally, individual variation in response is significant—some patients showed substantial cognitive preservation while others did not, and we do not yet understand which biological markers or patient characteristics predict who will benefit. Cognito’s Phase III trial should clarify these questions, but until those results are available, gamma stimulation should be considered experimental.

What Are the Important Limitations and Unknowns?

What Is the Role of Patient Selection and Disease Stage?

The evidence to date suggests that gamma stimulation may be most effective for mild cognitive impairment and mild dementia, when neural networks retain greater plasticity and capacity to respond to intervention. The five-patient study, for example, involved only individuals with mild Alzheimer’s disease. This contrasts with advanced dementia, where neuronal loss is more extensive and the brain’s capacity for functional reorganization may be diminished. A 65-year-old with recent memory loss may have a fundamentally different response profile than an 85-year-old with moderate dementia and multiple comorbidities.

Patient motivation and adherence will likely determine real-world effectiveness. One hour of daily stimulation is a significant commitment—substantially more than taking a pill. Patients and families who understand the experimental nature of the treatment and are motivated to participate actively may have better outcomes than those viewing it passively as a clinical intervention. The Phase III trial results should provide clarity on which patient populations and disease stages show the most promise.

What Do Ongoing Trials Mean for the Field?

Cognito Therapeutics’ Phase III trial, underway for more than a year as of March 2025, represents a critical inflection point for gamma stimulation’s future. This trial is measuring white matter preservation—the structural integrity of neural connections—alongside cognitive and functional measures. White matter preservation is a mechanistically meaningful outcome; if 40 Hz stimulation preserves white matter architecture, that would provide strong evidence that the intervention is working through the proposed biological mechanisms rather than through placebo or expectancy effects.

The growing evidence base—with multiple labs worldwide publishing supportive research in 2025 and 2026—suggests that gamma stimulation is attracting serious scientific attention and investment. If the Phase III trial demonstrates meaningful cognitive or functional benefit, we could see gamma stimulation moving toward clinical approval within the next 3–5 years, potentially offering the first truly non-pharmacological disease-modifying intervention for Alzheimer’s. However, regulatory approval and clinical adoption would require not only efficacy but also demonstration of long-term safety and cost-effectiveness compared to existing treatments.

Conclusion

Gamma frequency stimulation represents a promising but still-experimental approach to slowing Alzheimer’s disease progression. The underlying science is sound, preclinical evidence is encouraging, and early clinical results show cognitive preservation in some patients with no observed adverse events. However, current human data involve small numbers of patients, short follow-up periods, and limited assessment of individual variation in response. The distinction between slowing decline and reversing cognitive loss is important; the evidence to date supports the former but not the latter.

The field is at a critical juncture with Phase III trials underway. If those trials demonstrate meaningful benefit in a larger, more diverse patient population, gamma stimulation could become a valuable option alongside or instead of current medications. For patients and families considering participation in clinical trials, the decision should involve careful discussion with their neurologist about the experimental nature of the treatment, the realistic expectations for outcomes, and the commitment required for daily stimulation sessions. Those interested in staying informed should watch for Phase III trial results expected in the coming years.